Terumo (OTCMKTS:TRUMY) Hits New 12-Month Low – Here’s Why

Terumo Corp. (OTCMKTS:TRUMYGet Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $13.01 and last traded at $13.46, with a volume of 2708 shares. The stock had previously closed at $13.72.

Terumo Stock Performance

The company has a market cap of $19.16 billion, a P/E ratio of 21.82 and a beta of 0.75. The company has a quick ratio of 1.46, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average price of $14.65 and a 200-day moving average price of $16.18.

Terumo (OTCMKTS:TRUMYGet Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.75 billion. Terumo had a net margin of 12.35% and a return on equity of 9.39%.

About Terumo

(Get Free Report)

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

Read More

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.